医学
传统PCI
经皮冠状动脉介入治疗
血管内超声
支架
心肌梗塞
放射科
光学相干层析成像
随机对照试验
内科学
心脏病学
血管造影
作者
Ziad A. Ali,Ulf Landmesser,Keyvan Karimi Galougahi,Akiko Maehara,Mitsuaki Matsumura,Richard Shlofmitz,Giulio Guagliumi,Matthew J. Price,Jonathan Michael Hill,Takashi Akasaka,Francesco Prati,Hiram Grando Bezerra,William C. Wijns,Gary S. Mintz,Ori Ben‐Yehuda,Robert J. McGreevy,Zhen Zhang,Richard R. Rapoza,Nick E.J. West,Gregg W. Stone
出处
期刊:Eurointervention
[European Association of Percutaneous Cardiovascular Interventions]
日期:2021-01-01
卷期号:16 (13): 1092-1099
被引量:114
标识
DOI:10.4244/eij-d-20-00501
摘要
AIMS: Randomised trials have demonstrated improvement in clinical outcomes with intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) compared with angiography-guided PCI. The ILUMIEN III trial demonstrated non-inferiority of an optical coherence tomography (OCT)- versus IVUS-guided PCI strategy in achieving similar post-PCI lumen dimensions. ILUMIEN IV is a large-scale, multicentre, randomised trial designed to demonstrate the superiority of OCT- versus angiography-guided stent implantation in patients with high-risk clinical characteristics (diabetes) and/or complex angiographic lesions in achieving larger post-PCI lumen dimensions and improving clinical outcomes. METHODS AND RESULTS: ILUMIEN IV is a prospective, single-blind clinical investigation that will randomise between 2,490 and 3,656 patients using an adaptive design to OCT-guided versus angiography-guided coronary stent implantation in a 1:1 ratio. The primary endpoints are: (1) post-PCI minimal stent area assessed by OCT in each randomised arm, and (2) target vessel failure, the composite of cardiac death, target vessel myocardial infarction, or ischaemia-driven target vessel revascularisation. Clinical follow-up will continue for up to two years. The trial is currently enrolling, and the principal results are expected in 2022. CONCLUSIONS: The large-scale ILUMIEN IV randomised controlled trial will evaluate the effectiveness of OCT-guided versus angiography-guided PCI in improving post-PCI lumen dimensions and clinical outcomes in patients with diabetes and/or with complex coronary lesions. TRIAL REGISTRATION: NCT03507777.
科研通智能强力驱动
Strongly Powered by AbleSci AI